S&P 500   3,769.96 (-2.07%)
DOW   30,433.44 (-1.63%)
QQQ   321.13 (-2.27%)
AAPL   142.55 (-0.43%)
MSFT   232.36 (+0.01%)
FB   273.28 (-3.11%)
GOOGL   1,821.35 (-4.54%)
AMZN   3,251.36 (-2.25%)
TSLA   875.40 (-0.87%)
NVDA   517.02 (-3.79%)
BABA   262.00 (-1.47%)
CGC   38.19 (+7.52%)
GE   10.76 (-4.69%)
MU   75.68 (-4.82%)
AMD   89.29 (-5.72%)
NIO   57.32 (-4.96%)
T   29.08 (-2.25%)
F   10.79 (-3.57%)
ACB   11.41 (+6.94%)
BA   192.94 (-4.51%)
DIS   163.06 (-3.83%)
NFLX   533.00 (-5.15%)
GILD   65.59 (-1.66%)
S&P 500   3,769.96 (-2.07%)
DOW   30,433.44 (-1.63%)
QQQ   321.13 (-2.27%)
AAPL   142.55 (-0.43%)
MSFT   232.36 (+0.01%)
FB   273.28 (-3.11%)
GOOGL   1,821.35 (-4.54%)
AMZN   3,251.36 (-2.25%)
TSLA   875.40 (-0.87%)
NVDA   517.02 (-3.79%)
BABA   262.00 (-1.47%)
CGC   38.19 (+7.52%)
GE   10.76 (-4.69%)
MU   75.68 (-4.82%)
AMD   89.29 (-5.72%)
NIO   57.32 (-4.96%)
T   29.08 (-2.25%)
F   10.79 (-3.57%)
ACB   11.41 (+6.94%)
BA   192.94 (-4.51%)
DIS   163.06 (-3.83%)
NFLX   533.00 (-5.15%)
GILD   65.59 (-1.66%)
S&P 500   3,769.96 (-2.07%)
DOW   30,433.44 (-1.63%)
QQQ   321.13 (-2.27%)
AAPL   142.55 (-0.43%)
MSFT   232.36 (+0.01%)
FB   273.28 (-3.11%)
GOOGL   1,821.35 (-4.54%)
AMZN   3,251.36 (-2.25%)
TSLA   875.40 (-0.87%)
NVDA   517.02 (-3.79%)
BABA   262.00 (-1.47%)
CGC   38.19 (+7.52%)
GE   10.76 (-4.69%)
MU   75.68 (-4.82%)
AMD   89.29 (-5.72%)
NIO   57.32 (-4.96%)
T   29.08 (-2.25%)
F   10.79 (-3.57%)
ACB   11.41 (+6.94%)
BA   192.94 (-4.51%)
DIS   163.06 (-3.83%)
NFLX   533.00 (-5.15%)
GILD   65.59 (-1.66%)
S&P 500   3,769.96 (-2.07%)
DOW   30,433.44 (-1.63%)
QQQ   321.13 (-2.27%)
AAPL   142.55 (-0.43%)
MSFT   232.36 (+0.01%)
FB   273.28 (-3.11%)
GOOGL   1,821.35 (-4.54%)
AMZN   3,251.36 (-2.25%)
TSLA   875.40 (-0.87%)
NVDA   517.02 (-3.79%)
BABA   262.00 (-1.47%)
CGC   38.19 (+7.52%)
GE   10.76 (-4.69%)
MU   75.68 (-4.82%)
AMD   89.29 (-5.72%)
NIO   57.32 (-4.96%)
T   29.08 (-2.25%)
F   10.79 (-3.57%)
ACB   11.41 (+6.94%)
BA   192.94 (-4.51%)
DIS   163.06 (-3.83%)
NFLX   533.00 (-5.15%)
GILD   65.59 (-1.66%)
Log in
NASDAQ:GTHX

G1 Therapeutics Stock Forecast, Price & News

$21.91
+0.95 (+4.53 %)
(As of 01/27/2021 02:33 PM ET)
Add
Compare
Today's Range
$20.49
Now: $21.91▼
$22.62
50-Day Range
$17.58
MA: $19.39▼
$21.69
52-Week Range
$8.80
Now: $21.91▼
$25.79
Volume122,680 shs
Average Volume1.09 million shs
Market Capitalization$833.59 million
P/E RatioN/A
Dividend YieldN/A
Beta2.44
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2 clinical trials for patients with extensive-stage small cell lung cancer(SCLC), as well as Phase 2 clinical trial for patients with first-line (SCLC) and metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase 1b/2a clinical trials for the treatment of breast cancer and in Phase 1b clinical trial for non-small cell lung cancer; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase I/2 clinical trial. G1 Therapeutics, Inc. has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
G1 Therapeutics logo

MarketRank™

Overall MarketRank™

1.51 out of 5 stars

Medical Sector

408th out of 1,925 stocks

Pharmaceutical Preparations Industry

209th out of 773 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GTHX
Previous Symbol
CUSIPN/A
CIK1560241
Webwww.g1therapeutics.com
Phone919-213-9835
Employees104
Year FoundedN/A

Debt

Debt-to-Equity Ratio0.10
Current Ratio7.45
Quick Ratio7.45

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$6.80 per share
Price / Book3.22

Profitability

EPS (Most Recent Fiscal Year)($3.27)
Net Income$-122,450,000.00
Net MarginsN/A
Return on Equity-49.35%
Return on Assets-41.53%

Miscellaneous

Outstanding Shares38,046,000
Market Cap$833.59 million
Next Earnings Date2/24/2021 (Estimated)
OptionableOptionable
$21.91
+0.95 (+4.53 %)
(As of 01/27/2021 02:33 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GTHX News and Ratings via Email

Sign-up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions

How has G1 Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

G1 Therapeutics' stock was trading at $14.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GTHX stock has increased by 53.7% and is now trading at $22.27.
View which stocks have been most impacted by COVID-19.

Is G1 Therapeutics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" G1 Therapeutics stock.
View analyst ratings for G1 Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than G1 Therapeutics?

Wall Street analysts have given G1 Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but G1 Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is G1 Therapeutics' next earnings date?

G1 Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for G1 Therapeutics.

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) released its quarterly earnings results on Wednesday, November, 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.06. The business earned $26.60 million during the quarter, compared to analyst estimates of $40 million.
View G1 Therapeutics' earnings history.

What price target have analysts set for GTHX?

7 brokerages have issued 1-year price objectives for G1 Therapeutics' shares. Their forecasts range from $21.00 to $82.00. On average, they anticipate G1 Therapeutics' share price to reach $50.17 in the next year. This suggests a possible upside of 125.3% from the stock's current price.
View analysts' price targets for G1 Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of G1 Therapeutics' key competitors?

Some companies that are related to G1 Therapeutics include Prelude Therapeutics (PRLD), ALX Oncology (ALXO), Pacira BioSciences (PCRX), IGM Biosciences (IGMS), Rocket Pharmaceuticals (RCKT), Taro Pharmaceutical Industries (TARO), Global Blood Therapeutics (GBT), Amarin (AMRN), I-Mab (IMAB), Xencor (XNCR), CytoDyn (CYDY), Intra-Cellular Therapies (ITCI), Axsome Therapeutics (AXSM), Cryoport (CYRX) and Karuna Therapeutics (KRTX).
View all of GTHX's competitors.

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

Who are G1 Therapeutics' key executives?

G1 Therapeutics' management team includes the following people:
  • Ms. Jennifer K. Moses, Chief Financial Officer (Age 46, Pay $441.6k)
  • Dr. Mark A. Velleca, Sr. Advisor & Director (Age 57, Pay $878.21k)
  • Dr. Rajesh K. Malik, Chief Medical Officer and Sr. VP of R&D (Age 62, Pay $560.17k)
  • Mr. Mark Avagliano, Chief Bus. Officer (Age 45, Pay $559.74k)
  • Mr. John E. Bailey Jr., CEO, Pres & Director (Age 56)
  • Mr. Terry L. Murdock, Chief Operating Officer (Age 61)
  • Mr. Alexander D. Smith M.S., VP of Technical Operations
  • Dr. Jay C. Strum, Chief Scientific Officer (Age 57)
  • Mr. Jeff Macdonald, Sr. Director of Investor Relations & Corp. Communications
  • Mr. Blake Jensen, VP of Quality & Compliance

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an initial public offering (IPO) on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.63%), Pacer Advisors Inc. (0.01%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own G1 Therapeutics stock include Glenn P Muir, James S Hanson, Mark A Velleca, Rajesh Malik and Seth Rudnick.
View institutional ownership trends for G1 Therapeutics.

Which institutional investors are buying G1 Therapeutics stock?

GTHX stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Pacer Advisors Inc., and Nisa Investment Advisors LLC. Company insiders that have bought G1 Therapeutics stock in the last two years include Glenn P Muir, and James S Hanson.
View insider buying and selling activity for G1 Therapeutics or or view top insider-buying stocks.

How do I buy shares of G1 Therapeutics?

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $22.27.

How big of a company is G1 Therapeutics?

G1 Therapeutics has a market capitalization of $847.28 million. The company earns $-122,450,000.00 in net income (profit) each year or ($3.27) on an earnings per share basis. G1 Therapeutics employs 104 workers across the globe.

What is G1 Therapeutics' official website?

The official website for G1 Therapeutics is www.g1therapeutics.com.

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.